Comparative Pharmacology
Head-to-head clinical analysis: AVINZA versus DARVON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AVINZA versus DARVON.
AVINZA vs DARVON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AVINZA (morphine sulfate) is a full opioid agonist that binds to mu-opioid receptors in the CNS, producing analgesia by altering pain perception and emotional response to pain.
Propoxyphene is a mu-opioid receptor agonist that inhibits ascending pain pathways by binding to opioid receptors in the CNS, altering pain perception. It also has weak local anesthetic effects.
Oral, 30 mg once daily (q24h) for opioid-naïve patients; titrate based on response. Maximum daily dose 160 mg. Administer with food to minimize peak effects.
Propoxyphene hydrochloride (Darvon) for moderate to severe pain: 65 mg orally every 4 hours as needed; maximum 390 mg/day.
None Documented
None Documented
Terminal elimination half-life of morphine is approximately 1.5-2 hours; however, due to the extended-release formulation, the effective half-life is prolonged to about 9-11 hours, allowing once-daily dosing.
6-12 hours (parent drug); norpropoxyphene half-life 30-36 hours, accumulates with repeated dosing, increasing risk of toxicity.
Primarily renal (approximately 90% as morphine metabolites, mainly morphine-3-glucuronide and morphine-6-glucuronide); biliary/fecal excretion accounts for less than 10%.
Primarily hepatic metabolism to norpropoxyphene, then renal excretion of metabolites; <20% excreted unchanged in urine; minor biliary/fecal elimination.
Category C
Category C
Opioid Analgesic
Opioid Analgesic